Deucravacitinib (Sotyktu)

Key Messages

• CADTH recommends that Sotyktu not be reimbursed by public drug plans for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
• The evidence from 2 clinical trials was insufficient to determine that Sotyktu offered treatment benefits over the currently available advanced treatments in Canada for the treatment of moderate to severe plaque psoriasis in adults.
• No evidence was found that directly compared Sotyktu to newer interleukin (IL)-17 and IL-23 biologics, and the indirect evidence suggested that Sotyktu was less effective at improving skin plaques than several biologics (including IL-17 and IL-23 biologics) that are available and reimbursed in Canada.
• CADTH concluded that there was not enough evidence to show that Sotyktu met the needs of patients with moderate to severe plaque psoriasis not already addressed by other available treatments.